Sotera Health Company

NasdaqGS:SHC Stock Report

Market Cap: US$3.2b

Sotera Health Past Earnings Performance

Past criteria checks 1/6

Sotera Health's earnings have been declining at an average annual rate of -5%, while the Life Sciences industry saw earnings growing at 4.5% annually. Revenues have been growing at an average rate of 7.6% per year. Sotera Health's return on equity is 11%, and it has net margins of 4%.

Key information

-5.0%

Earnings growth rate

-3.8%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate7.6%
Return on equity11.0%
Net Margin4.0%
Next Earnings Update01 May 2025

Recent past performance updates

There May Be Reason For Hope In Sotera Health's (NASDAQ:SHC) Disappointing Earnings

Mar 07
There May Be Reason For Hope In Sotera Health's (NASDAQ:SHC) Disappointing Earnings

Recent updates

What Does Sotera Health Company's (NASDAQ:SHC) Share Price Indicate?

Apr 24
What Does Sotera Health Company's (NASDAQ:SHC) Share Price Indicate?

Is Sotera Health (NASDAQ:SHC) A Risky Investment?

Mar 31
Is Sotera Health (NASDAQ:SHC) A Risky Investment?

There May Be Reason For Hope In Sotera Health's (NASDAQ:SHC) Disappointing Earnings

Mar 07
There May Be Reason For Hope In Sotera Health's (NASDAQ:SHC) Disappointing Earnings

Some Confidence Is Lacking In Sotera Health Company's (NASDAQ:SHC) P/S

Feb 26
Some Confidence Is Lacking In Sotera Health Company's (NASDAQ:SHC) P/S

Why Sotera Health Company (NASDAQ:SHC) Could Be Worth Watching

Jan 06
Why Sotera Health Company (NASDAQ:SHC) Could Be Worth Watching

Here's Why Sotera Health (NASDAQ:SHC) Has A Meaningful Debt Burden

Dec 05
Here's Why Sotera Health (NASDAQ:SHC) Has A Meaningful Debt Burden
author-image

Sterigenics' Expansion And Smart Pricing Poised For Sustained Revenue And Margin Growth

Sep 02 Sotera Health's strategic pricing and capacity expansion reflect confidence in maintaining or growing future revenue and net margins, despite economic pressures.

Sotera Health Company's (NASDAQ:SHC) P/S Still Appears To Be Reasonable

Sep 02
Sotera Health Company's (NASDAQ:SHC) P/S Still Appears To Be Reasonable

Sotera Health (NASDAQ:SHC) Takes On Some Risk With Its Use Of Debt

Jun 25
Sotera Health (NASDAQ:SHC) Takes On Some Risk With Its Use Of Debt

Sotera Health Company (NASDAQ:SHC) Shares Could Be 42% Below Their Intrinsic Value Estimate

May 30
Sotera Health Company (NASDAQ:SHC) Shares Could Be 42% Below Their Intrinsic Value Estimate

The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%

Mar 21
The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%

Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models

Mar 01
Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models

McIntyre Partnerships - Sotera Health Company: A Notable Outlier At A Discount

Feb 08

Is Sotera Health (NASDAQ:SHC) A Risky Investment?

Feb 06
Is Sotera Health (NASDAQ:SHC) A Risky Investment?

Investors Still Aren't Entirely Convinced By Sotera Health Company's (NASDAQ:SHC) Revenues Despite 26% Price Jump

Dec 28
Investors Still Aren't Entirely Convinced By Sotera Health Company's (NASDAQ:SHC) Revenues Despite 26% Price Jump

Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 33% Above Its Share Price

Dec 11
Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 33% Above Its Share Price

An Intrinsic Calculation For Sotera Health Company (NASDAQ:SHC) Suggests It's 37% Undervalued

Sep 10
An Intrinsic Calculation For Sotera Health Company (NASDAQ:SHC) Suggests It's 37% Undervalued

Sotera Health Company (NASDAQ:SHC) Shares Could Be 24% Below Their Intrinsic Value Estimate

Jun 05
Sotera Health Company (NASDAQ:SHC) Shares Could Be 24% Below Their Intrinsic Value Estimate

Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 34%?

Feb 13
Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 34%?

Revenue & Expenses Breakdown

How Sotera Health makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:SHC Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 241,100442050
30 Sep 241,120701750
30 Jun 241,098401670
31 Mar 241,077551630
31 Dec 231,049511860
30 Sep 23991-3061800
30 Jun 23976-2681770
31 Mar 23988-2611730
31 Dec 221,004-2341660
30 Sep 229931211630
30 Jun 229711231580
31 Mar 229561351520
31 Dec 219311151490
30 Sep 21907361520
30 Jun 2188191500
31 Mar 21842-261400
31 Dec 20818-391370
30 Sep 20795-231190
30 Jun 20790-281280
31 Mar 20772-291320
31 Dec 19778-211320
31 Dec 18746-61260

Quality Earnings: SHC has a large one-off loss of $56.9M impacting its last 12 months of financial results to 31st December, 2024.

Growing Profit Margin: SHC's current net profit margins (4%) are lower than last year (4.9%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SHC has become profitable over the past 5 years, growing earnings by -5% per year.

Accelerating Growth: SHC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SHC had negative earnings growth (-13.2%) over the past year, making it difficult to compare to the Life Sciences industry average (-4.1%).


Return on Equity

High ROE: SHC's Return on Equity (11%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/27 01:00
End of Day Share Price 2025/04/25 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sotera Health Company is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PolarkBaird
Luke SergottBarclays
Patrick DonnellyCitigroup Inc